Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
How Much Time Do Focal Treatments for Retinoblastoma Add to Anesthetic Exposure?
Abramson DH, Gaccione J, Bracken C, Liu T, Guarini E, Bobin A, Foerch A, Robbins MA, Rojas RD, Francis JH. Abramson DH, et al. Among authors: bobin a. Ocul Oncol Pathol. 2024 Sep;10(3):182-188. doi: 10.1159/000539488. Epub 2024 May 31. Ocul Oncol Pathol. 2024. PMID: 39224528 Free PMC article.
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM.
Malard F, Bobin A, Labopin M, Karlin L, Frenzel L, Roussel M, Vignon M, Godet S, Chalopin T, Moyer P, Chalayer E, Orsini Piocelle F, Mariette C, Croizier C, Sohn C, Dib M, Le Calloch R, Ali-Ammar N, Loirat M, Benbrahim O, Payssot A, Trebouet A, Perrot A, Leleu X, Mohty M. Malard F, et al. Among authors: bobin a. Blood Cancer J. 2024 Dec 18;14(1):219. doi: 10.1038/s41408-024-01200-w. Blood Cancer J. 2024. PMID: 39695076 Free PMC article. No abstract available.
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program.
Perrot A, Hulin C, Boumendil A, Manjra H, Leveque A, Croizier C, Dony A, Mohty M, Roussel M, Manier S, Orsini-Piocelle F, Bauschert L, Bobin A, Frenzel L, Vincent L, Breal C, Eveillard JR, Gerome T, Tiab M, Chalayer E, Belkhir R, Mariette C, Moyer P, Chalopin T, Cherel B, Montes L, Coste A, Tabrizi R, Karlin L, Robu D, Huguet A, Harel S, Moreau P. Perrot A, et al. Among authors: bobin a. Haematologica. 2024 Nov 21. doi: 10.3324/haematol.2024.286118. Online ahead of print. Haematologica. 2024. PMID: 39568438 Free article.
Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with high-risk cytogenetics: the IFM 2014-01 study.
Bobin A, Manier S, De Keizer J, Srimani JK, Hulin C, Karlin L, Caillot D, Lafon I, Mariette C, Araujo C, Arnulf B, Bareau B, Belhadj K, Benboubker L, Braun T, Calmettes C, Decaux O, Dib M, Demarquette H, Jacquet C, Sonntag C, Godet S, Jaccard A, Lenain P, Macro M, Richez-Olivier V, Tiab M, Vincent L, Zerazhi H, Pétillon MO, Rollet S, Gardeney H, Durand G, Levy A, Touzeau C, Perrot A, Moreau P, Facon T, Corre J, Ragot S, Avet-Loiseau H, Leleu X. Bobin A, et al. Haematologica. 2024 Nov 14. doi: 10.3324/haematol.2024.285916. Online ahead of print. Haematologica. 2024. PMID: 39540213 Free article.
Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY Cohort.
Chalopin T, Macro M, Decaux O, Royer B, Gounot R, Bobin A, Karlin L, Mohty M, Frenzel L, Perrot A, Manier S, Vincent L, Dib M, Slama B, Richez V, Allangba O, Zunic P, Newinger-Porte M, Mariette C, Joly B, Gay J, Botoc I, Malfuson JV, Garlantezec R, Hulin C. Chalopin T, et al. Among authors: bobin a. Clin Lymphoma Myeloma Leuk. 2024 Sep 30:S2152-2650(24)02350-4. doi: 10.1016/j.clml.2024.09.006. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39462749
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.
Leleu X, Hulin C, Lambert J, Bobin A, Perrot A, Karlin L, Roussel M, Montes L, Cherel B, Chalopin T, Slama B, Chretien ML, Laribi K, Dingremont C, Roul C, Mariette C, Rigaudeau S, Calmettes C, Dib M, Tiab M, Vincent L, Delaunay J, Santagostino A, Macro M, Bourgeois E, Orsini-Piocelle F, Gay J, Bareau B, Bigot N, Vergez F, Lebreton P, Tabrizi R, Waultier-Rascalou A, Frenzel L, Le Calloch R, Chalayer E, Braun T, Lachenal F, Corm S, Kennel C, Belkhir R, Bladé JS, Joly B, Richez-Olivier V, Gardeney H, Demarquette H, Robu-Cretu D, Garderet L, Newinger-Porte M, Kasmi A, Royer B, Decaux O, Arnulf B, Belhadj K, Touzeau C, Mohty M, Manier S, Moreau P, Avet-Loiseau H, Corre J, Facon T. Leleu X, et al. Among authors: bobin a. Nat Med. 2024 Aug;30(8):2235-2241. doi: 10.1038/s41591-024-03050-2. Epub 2024 Jun 3. Nat Med. 2024. PMID: 38830994 Free PMC article. Clinical Trial.
Posterior reversible encephalopathy syndrome (PRES) and myeloma.
Ghanem R, Glaisner S, Bobin A, Ronchetti AM, Cereja S, Joly B, Salanoubat C, Fouquet G. Ghanem R, et al. Among authors: bobin a. Leuk Res Rep. 2023 Dec 29;21:100407. doi: 10.1016/j.lrr.2023.100407. eCollection 2024. Leuk Res Rep. 2023. PMID: 38260821 Free PMC article.
43 results